REGULATORY

• MID-NET Working Group Agrees on Flat Access Fees for Drug Makers’ PMS Use
  November 30, 2016

• Shiozaki Hints at Possible Drug Price Survey in Different Method
  November 30, 2016

• Before Micatrio, Patient Must Take 3 Contained Compounds for at Least 8 Weeks: MHLW
  November 29, 2016

• Japan Ophthalmologists Association Calls for Reductions in NHI Prices of High-Cost Drugs
  November 29, 2016

• LDP Study Group Kicks Off to Put Brakes on Hasty Push for Biosimilars
  November 28, 2016

• Eltrombopag, Nusinersen Designated as Orphan Drugs
  November 28, 2016

• MHLW Advisory Panel OKs Biogen’s Tecfidera, Other Drugs
  November 28, 2016

• Annual Price Revision Push Gaining Momentum; PM Wants Pricing Revamp Policy by Year-End
  November 28, 2016

• MHLW Panel OKs Celgene’s Apremilast, 2 Other NMEs
  November 25, 2016

• MHLW Looks to Extend MID-NET to Cover Clinic Data: Bureau Chief
  November 25, 2016

• More Patient Participation Needed to Promote Drug Development, Safety Measures: MHLW Official
  November 25, 2016

• Keytruda Clears MHLW Panel for Both 1st-Line, 2nd-Line NSCLC
  November 25, 2016

• Polaprezinc Ordered to Add Copper Deficiency in ADR List
  November 24, 2016

• LDP’s Health Committee Demands Enhanced R&D Tax Break as Key Priority
  November 24, 2016

• MHLW OKs Janssen’s HIV Combo Pill Prezcobix
  November 24, 2016

• AMED to Allocate 240 Million Yen for R&D of Innovative Cancer Treatments, Including CAR-T Cell Therapy
  November 24, 2016

• MHLW to Announce Opdivo’s New Prices on Nov. 24
  November 24, 2016

• MHLW to Revise Rules on Development Requests for Unapproved Drugs
  November 22, 2016

• Council OKs Public Knowledge-Based Application for Tamiflu’s New Pediatric Dosage
  November 22, 2016

• MHLW to Set Up Quake-Resistant Warehouse to Stockpile Vaccines Using Supplementary Budget for FY2016
  November 21, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 266
• 267
• 268
• 269
• 270
• 271
• 272
• 273
• 274
• …
• Next ›
• 最終 »